back to top
JammuAmrita Hospital, Faridabad collaborates with ImmunoACT to introduce CAR T-cell Therapy for...

Amrita Hospital, Faridabad collaborates with ImmunoACT to introduce CAR T-cell Therapy for Blood Cancer Patients


NL Correspondent

Tawi: Amrita Hospital, Faridabad, in collaboration with ImmunoACT which is an IIT-Bombay incubated company, has introduced CAR T-cell (Chimeric antigen receptor) therapy for certain cancer patients, which is considered a significant breakthrough in B cell lymphoma and leukemia treatment, with promising results in relapsed and refractory patients. Four patients of B-cell Lymphoma have already undergone or are undergoing this therapy at Amrita Hospital so far and they are under follow-up.Dr. Prashant Mehta, Senior Consultant, Program Director (Lymphoid neoplasms & Cellular Therapy), Dept. of Medical Oncology / Hematoncology / BMT, Amrita Hospital, Faridabad said, “The treatment of cancer has improved immensely in the last few decades, and now we are in an era where we are able to harness the power of our immunity and channelize its strength to target cancer cells, with minimum effects on other organs or the body as a whole. A novel and refined way of harnessing our immune cells is CAR T-cell therapy which, in true sense of the word, is composed of ‘living drugs.' CAR-T cells are living T-lymphocytes of a patient which are genetically reprogrammed to target specific proteins on the surface of cancer cells and kill them. As per ImmunoACT's Founder and CEO – Dr Rahul Purwar “Our vision is to ensure that cutting-edge cell and gene therapy products are available in through indigenous R&D that provides access at affordable price. We need to put India on the global map in the space of advanced medicines.” Adding, ImmunoACT's Co-founder, and Director – Strategy & Development, Shirish Arya said, “NexCAR19's clinical results are benchmarked with the best-in-class globally in terms of efficacy and outperforms on its safety profile. We are very proud to partner with Amrita Hospitals to launch this made-in-India product for the benefit of patients across all sections of society in India”.Dr. Prashant Mehta added: “At present, CAR T-cell therapy is helpful in relapsed /refractory B cell ALL, more as a bridge to Allogenic BMT, except in patients who are not eligible for intensive treatment where it can be used as a definitive treatment. Similarly, it is useful in relapsed/refractory B cell lymphoma and Myeloma. This therapy does not work for all patients, and one must discuss with the treating oncologist whether they could be candidates for this treatment. CAR T-cell therapy, in suitable high grade B cell Lymphoma patients can provide a response rate of 70% and long-term cure rate of about 40%. In relapsed/refractory B cell ALL (Acute Lymphoblastic Leukemia) response rates are 90% and long-term cure rate is about 60% for CAR T-cell therapy.”Said Dr. Sanjeev Singh, Medical Director, Amrita Hospital, Faridabad, “Administration of CAR T-cell therapy at Amrita Hospital opens the door to many more patients to avail this treatment, as this therapy has so far been inaccessible to most Indians. We are closely collaborating with researchers in India and abroad in the field of CAR immunotherapy and aim to improve access to CAR immune cell therapies for those in need. We are now developing a -level collaborative cell therapy lab which will cater to the needs of patients on a larger scale. The goal is to develop ‘Institutional CAR T-cells' in our own hospital which will improve access to this treatment and bring it within reach of most of the Indian population.”“Amrita Hospital, Faridabad has been the first centre in Northern India to launch a CAR-T cell therapy program.”



The Northlines is an independent source on the Web for news, facts and figures relating to Jammu, Kashmir and Ladakh and its neighbourhood.

Share post:


More like this

Essential Parfums: Redefining Haute Perfumery with Sustainability and Craftmanship

Jammu Tawi: Baccarose is thrilled to introduce Essential Parfums,...

Vitesco Technologies receives 2 German Brand Awards

Jammu Tawi: Vitesco Technologies, a leading international supplier of...

Divisional Commissioner and ADGP of Jammu Engage in Dialogue with Local Civil Society Members

Invited suggestions for better conduct of Shri Amarnathji...

Jammu Police Warns Public Against False Social Media Reports on Night Outings

Jammu, June 14: The  Jammu and Kashmir Police on Friday cautioned...